Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
GoMed is a clinical decision support system for TBM (tuberculous meningitis), with the headline claim “Smarter Decisions. Faster Diagnosis.” Based on the captured content, it requires users to log in, and its primary users include clinicians and neurologists. Its core goal is to help conduct structured diagnostic assessments for suspected TBM cases.
The product navigation includes modules such as Dashboard, New Diagnosis, Case History, Reference, TBM Criteria, and Treatment Guide. The Dashboard can display total cases, Probable/Definite TBM, Possible TBM, today’s assessments, and recent cases. New Diagnosis is used to initiate a new TBM assessment. The system description indicates that suspected cases are scored according to the Uniform Case Definition criteria. Overall, it looks more like a vertical, specialty-focused CDSS than a general electronic medical record system or an integrated hospital management platform.
The captured page content does not disclose plans, pricing, payment methods, a free version, or trial arrangements. It also does not show whether institutional purchasing is supported, or whether billing is per user or based on case volume. The deployment model is also unclear. Although the page appears to be a web-based login experience, the text alone is not enough to determine whether it is a pure cloud service, private deployment, or hybrid deployment.
The page includes a login form and role-related text such as “Clinician” and “Neurologist,” suggesting that the system at least has a concept of user identity. However, it does not disclose enterprise-level capabilities such as team collaboration, permission controls, audit logs, or data isolation. For medical software, patient data security, privacy compliance, and boundaries of clinical responsibility are especially important, but the captured content provides no information about HIPAA, GDPR, local healthcare compliance, encryption, or data storage. There is also no visible information about third-party integrations, APIs, or developer documentation.
Its main advantage is its very clear positioning: it builds a closed loop around TBM diagnosis through scoring, cases, criteria, and treatment references. It is suitable for infectious disease, neurology, or other medical teams that need decision support for TBM diagnosis and care. Its limitations are the lack of disclosed information on pricing, clinical validation, data security, integration capabilities, and service support. It is also not ideal for organizations that need a comprehensive CDSS, deep HIS/EMR integration, or a multi-disease knowledge base.
Access from China is unknown, and payment methods are not disclosed. If deployed in a Chinese medical institution, additional evaluation would be needed for network accessibility, cross-border data transfer, patient privacy, and local compliance requirements. Comparable options include UpToDate, BMJ Best Practice, DynaMed, or a hospital’s local CDSS, but GoMed’s differentiator is its stronger focus on the TBM use case.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on gomed.life official site.
gomed.life is an Unknown Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach gomed.life directly.